Clinical Trials Sponsored by Merck & Cie

Total 5306 results

Merck KGaA, Darmstadt, Germany

Completed

Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer (CHANGE2)

Carcinoma, Squamous Cell of Head and Neck

Germany
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) (PNEU-WAY)

Pneumococcal Infections

United States, France, Peru, South Africa, Thailand
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Advanced Solid Tumors

France, Germany, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Human Immunodeficiency Virus (HIV) Infection

United States, Germany
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Measles | Mumps | Varicella

France, Germany
Merck Sharp & Dohme LLC

Terminated

Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

Multiple Myeloma
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Urothelial Cancer
Merck Sharp & Dohme LLC

Terminated

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Multiple Myeloma
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

Pneumococcal Infections

United States, Brazil, Colombia, Dominican Republic, Greece, Italy, Panama
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) (PNEU-AGE)

Pneumococcal Infections

Taiwan, United States, Canada, Japan, Spain
Merck Sharp & Dohme LLC

Completed

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) (PNEU-TRUE)

Pneumococcal Infections | Pneumonia, Pneumococcal

United States, Australia, Chile, Denmark, Finland, United Kingdom
Merck Sharp & Dohme LLC

Completed

Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Multiple Myeloma
Merck Sharp & Dohme LLC

Completed

Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)

Varicella

Russian Federation
Merck Sharp & Dohme LLC

Completed

Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)

Relapsed or Refractory Multiple Myeloma
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

rrCLL | rrMM | rrDLBCL
Merck Sharp & Dohme LLC

Completed

Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)

Arthroplasty, Replacement, Knee | Neuromuscular Blockade | Arthroplasty, Replacement, Hip | Blood Coagulation | Antithrombotic Agents
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

Complicated Intra-abdominal Infection | Complicated Urinary Tract Infection

Japan
Merck Sharp & Dohme LLC

Completed

18F-FLT-PET in Breast Cancer (MK-0000-139)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

Chronic Hepatitis C Genotype 1
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

Hepatitis C Infection
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Chronic Hepatitis C (CHC)
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Varicella

United States
Merck Sharp & Dohme LLC

Completed

A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001) (Jade)

Dyssomnias | Sleep Disorders | Mental Disorder | Sleep Initiation and Maintenance Disorder; Elderly | Sleep Disorder, Intrinsic
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)

HIV Infections | HIV
Merck KGaA, Darmstadt, Germany

Terminated

TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment (TICON)

Infertility

Norway, Spain, France, Portugal, Canada, Denmark, Italy
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

Obstructive Sleep Apnea (OSA)

United States, Belgium
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

Lung Cancer | Mesothelioma
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC

Terminated

A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)

Rectal Neoplasms
Merck Sharp & Dohme LLC

Completed

MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)

HIV-1 Infection

Germany
Merck Sharp & Dohme LLC

Withdrawn

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Esophageal Neoplasms

China
Merck KGaA, Darmstadt, Germany

Completed

Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)

Osteoarthritis, Knee

Denmark
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)

Cancer | Pharmacokinetics

Belgium
Merck Sharp & Dohme LLC

Completed

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Gram-Positive Bacterial Infections
Merck KGaA, Darmstadt, Germany

Completed

A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment (FASSION)

Infertility

China
Merck Sharp & Dohme LLC

Terminated

Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Acute Cough

United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study

Healthy

Indonesia
Merck Sharp & Dohme LLC

Completed

Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection

Japan
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
Merck Sharp & Dohme LLC

Completed

Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Terminated

Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)

Hepatic Insufficiency | Antibacterial Agents

United States

3

Subscribe